|
10 Dec 2019 |
UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting
|
|
09 Dec 2019 |
Rocket Pharmaceuticals Announces Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I
|
|
09 Dec 2019 |
FORMA Therapeutics Announces Clinical Data for Sickle Cell Disease Candidate FT-4202, Demonstrating Multi-modal Activity of PKR Activation Increases Oxygen Affinity and Decreases Sickle Hemoglobin Polymerization, at 61st Annual ASH Meeting
|
|
09 Dec 2019 |
FORMA Therapeutics Announces Positive Preliminary Phase 1/2 IDH1m Inhibitor Olutasidenib Results Demonstrating Rapid Clinical Remissions and Mutation Clearance in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
|
|
09 Dec 2019 |
Seven and Eight BioPharmaceuticals, Inc. Announces Clinical Collaboration to Evaluate BDB001 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
|
|
09 Dec 2019 |
Celularity Presents Pre-Clinical and Clinical Data from its Allogeneic, Placental-Derived, Off-the-Shelf Cell Therapy Platform at the 2019 ASH Annual Meeting
|
|
09 Dec 2019 |
Xencor Presents Initial Data from Phase 1 Study of XmAb®13676 in B-cell Malignancies at the ASH Annual Meeting
|
|
09 Dec 2019 |
Samyang Biopharm USA, Inc. and Talix Therapeutics NV Announce Global Strategic Collaboration to Advance Novel Immuno-Oncology Therapeutic
|
|
09 Dec 2019 |
Magenta Therapeutics Demonstrates First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of Antibody-drug Conjugate
|
|
09 Dec 2019 |
Alpine Immune Sciences Presents ALPN-101 Phase 1 Healthy Volunteer Study Data and Details of Upcoming Phase I/II BALANCE GVHD Study at the 61st American Society of Hematology Annual Meeting
|
|
09 Dec 2019 |
IONTAS Antibody Enters Clinical Trial for Use in the Treatment of B Cell Acute Lymphoblastic Leukemia
|
|
09 Dec 2019 |
Sesen Bio Initiates Rolling Submission of BLA for Vicinium to FDA
|
|
09 Dec 2019 |
Sangamo Announces Preliminary Results From the First Three Patients in a Phase 1/2 Study Evaluating ST-400 Ex Vivo Gene-edited Cell Therapy in Beta Thalassemia
|
|
09 Dec 2019 |
Merck to Acquire ArQule, Advancing Leadership in Oncology
|
|
09 Dec 2019 |
Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy
|
|
09 Dec 2019 |
Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs
|
|
09 Dec 2019 |
Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
|
|
09 Dec 2019 |
Autolus Therapeutics Announces New Data Showcasing Clinical Progress of AUTO3 in B Cell Malignancies
|
|
09 Dec 2019 |
Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion
|
|
09 Dec 2019 |
ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix
|
